Anti-LMO3 antibody (70-150 C-Term)

Cat# NB-22-3937-200ul

Size : 200µg

Brand : Neo Biotech

Contact local distributor :


Phone : +1 850 650 7790

  • Western blot analysis of lysates from COS7 cells, using LMO3 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Western blot analysis of various cells using LMO3 Polyclonal Antibody

General Info

Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Mouse/Rat/Monkey
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-LIM domain only protein 3 (96-145 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:10000
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.

Information

Gene Symbol: LMO3
Gene ID: 55885
Uniprot ID: LMO3_HUMAN
Immunogen Region: 96-145 aa
Specificity: LMO3 Polyclonal Antibody detects endogenous levels of LMO3 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human LMO3 at the amino acid range 96-145

Description

Protein Name Lim Domain Only Protein 3
Lmo-3
Neuronal-Specific Transcription Factor Dat1
Rhombotin-3
Alternative Names Anti-Lim Domain Only Protein 3 antibody
Anti-Lmo-3 antibody
Anti-Neuronal-Specific Transcription Factor Dat1 antibody
Anti-Rhombotin-3 antibody
Anti-LMO3 antibody
Anti-RBTN3 antibody
Anti-RBTNL2 antibody
Anti-RHOM3 antibody

Information sourced from uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance